US2023201349A1PendingUtilityA1

Anhydrous sodium thiosulfate and formulations thereof

84
Assignee: FENNEC PHARMACEUTICALS INCPriority: Jul 3, 2018Filed: Feb 20, 2023Published: Jun 29, 2023
Est. expiryJul 3, 2038(~12 yrs left)· nominal 20-yr term from priority
Inventors:Thomas Claiborne LovelaceJoseph A. Moore, IiiChristopher Mckinnon LeeDaniel Logan Kirschner
A61K 47/26A61K 47/183A61K 33/243A61K 47/18A61K 9/08A61K 9/0019A61K 33/04A61K 47/20A61K 47/02C01B 17/64C01P 2002/72A61K 9/19A61P 35/00
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A pharmaceutical composition comprising a sodium thiosulfate at a concentration between about 0.3 M and about 0.6 M and further comprising glycine at a concentration between about 0.01 M and about 0.05 M. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition has a pH between about 8.5 and 8.9. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the sodium thiosulfate is aqueous anhydrous sodium thiosulfate. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition further comprises a base. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the base is sodium hydroxide. 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein the sodium thiosulfate is aqueous anhydrous sodium thiosulfate. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the concentration of glycine is about 0.01 M. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the concentration of glycine is about 0.02 M. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the concentration of glycine is about 0.03 M. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the concentration of glycine is about 0.05 M. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the concentration of the sodium thiosulfate is about 0.5 M. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition has a pH between about 8.5 and 8.9. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the sodium thiosulfate is aqueous anhydrous sodium thiosulfate. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutical composition further comprises a base. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the base is sodium hydroxide. 
     
     
         16 . The pharmaceutical composition of  claim 14 , wherein the sodium thiosulfate is aqueous anhydrous sodium thiosulfate. 
     
     
         17 . The pharmaceutical composition of  claim 11 , wherein the concentration of glycine is about 0.01 M. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein the concentration of glycine is about 0.02 M. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein the concentration of glycine is about 0.03 M. 
     
     
         20 . The pharmaceutical composition of  claim 11 , wherein the concentration of glycine is about 0.05 M.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.